Stealth BioTherapeutics OverviewLatest profit margin for Stealth BioTherapeutics: -Infinity% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2022
Trailing 12 months ending Mar 2022
As of the most recent data (March 2022), MITO shows a profit margin of -Infinity%. That is below the Healthcare sector average of 15.58%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average profit margin is about 15.58%. Stealth BioTherapeutics is at -Infinity%, which is lower that average. That is roughly Infinity% below the sector mean. Use the comparison chart on this page to see how MITO stacks up against individual peers as well.
Check the historical chart to see whether MITO's profit margin is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Stealth BioTherapeutics with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has Stealth BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -Infinity%) with ownership activity and broader fundamentals.
The Healthcare average profit margin is about 15.58%, while MITO is at -Infinity%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
